____________________________
Blockbusters like Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate, formerly known as X842, takes a new approach to provide improved management of esophagitis and GERD symptoms.
Today's GERD medication has significant shortcomings
De-risked development program – phase II study in planning
Linaprazan glurate provides improved
acid control
18.5 million
people in initial, niche target population
2,500
individuals exposed to the active metabolite of
linaprazan glurate
in clinical trials
Team with experience from development of Losec and Nexium